Your browser doesn't support javascript.
loading
Do hospitals that participate in COVID-19 research differ from non-trial hospitals? A cross-sectional study of US hospitals.
Kang, Daniel; Huang, Cher X; Yuen, Alexander D; Norris, Keith C; Vijayan, Tara.
Affiliation
  • Kang D; University of Illinois, Urbana Champaign, Champaign, USA. ddkang@illinois.edu.
  • Huang CX; Department of Medicine, Massachusetts General Hospital, Boston, USA.
  • Yuen AD; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA.
  • Norris KC; Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, USA.
  • Vijayan T; Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, USA.
Trials ; 24(1): 504, 2023 Aug 07.
Article in En | MEDLINE | ID: mdl-37550662
ABSTRACT

OBJECTIVES:

To compare hospitals that did and did not participate in clinical trials evaluating potential inpatient COVID-19 therapeutics.

METHODS:

We conducted a cross-sectional study of hospitals participating in trials that were registered on clinicaltrials.gov between April and August 2020. Using the 2019 RAND Hospital Dataset and 2019 American Community Survey, we used logistic regression modeling to compare hospital-level traits including demographic features between trial and non-trial hospitals.

RESULTS:

We included 488 hospitals that were participating in 298 interventional trials and 4232 non-participating hospitals. After controlling for demographic and other hospital traits, we found that teaching status (OR 2.11, 95% CI 1.52-2.95), higher patient acuity (OR 7.48, 4.39, 13.1), and location in the Northeast (OR 1.83, 95% CI 1.18, 2.85) and in wealthier counties (OR 1.32, 95% CI 1.16-1.51) were associated with increased odds of trial participation, while being in counties with more White residents was associated with reduced odds (OR 0.98, 95% CI 0.98-0.99).

CONCLUSIONS:

Hospitals participating and not participating in COVID-19 inpatient treatment clinical trials differed in many ways, resulting in important implications for the generalizability of trial data.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Type of study: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Trials Journal subject: MEDICINA / TERAPEUTICA Year: 2023 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Type of study: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Trials Journal subject: MEDICINA / TERAPEUTICA Year: 2023 Type: Article Affiliation country: United States